Mr. Russell is a veteran in the global biopharmaceutical industry with more than 30 years of experience in senior executive roles leading commercial execution, operations, and strategic acquisitions.
Mr. Russell served as the Chief Executive Officer of Shire plc (SHPG), a biopharmaceutical company, from June 2008 to April 2013. Mr. Russell served as the Chief Financial Officer of Shire from 1999 to 2008 and also served as its Principal Accounting Officer and Executive Vice President of Global Finance. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca for 19 years, most recently as Vice President of Corporate Finance at AstraZeneca plc (AZN).
Mr. Russell serves as Chairman of the Board of Directors of Revance Therapeutics, Inc. (RVNC) and also serves on the Board of Directors of Lineage Cell Therapeutics, Inc. (LCTX). Mr. Russell holds an honorary Doctor of Business Administration from Coventry University, U.K.